Testing effectiveness (Phase 2)Ended earlyNCT00509249
What this trial is testing
Aflibercept in Treating Patients With Myelodysplastic Syndromes
Who this might be right for
Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes+3 more
National Cancer Institute (NCI) 18